Literature DB >> 33893957

Choice of Tactics for Experimental Therapy of Chronic Heart Failure with ALM-802 Compound.

V V Barchukov1, I B Tsorin1, M B Vititnova1, A O Efimova1, A M Likhosherstov1, G V Mokrov1, S A Kryzhanovskii2.   

Abstract

The cardioprotective activity of ALM-802 compound was demonstrated in model experiments simulating postinfarction chronic heart failure in rats forming in 90 days after anterior transmural myocardial infarction. ALM-802 decreased the left ventricle and improved its inotropic function (p=0.038). This effect was observed in case of systematic administration of ALM-802 over 28 days (starting from day 91 after infarction modeling). This is apparently the minimum time for the cardioprotective effect of ALM-802 to prevent or treat the resulting heart failure, because short-term systematic therapy (15 days) produced no positive effect.

Entities:  

Keywords:  ALM-802 compound; anterior transmural myocardial infarction; chronic heart failure; experimental therapy terms of 15 days and 28 days; prevention and therapy

Year:  2021        PMID： 33893957     DOI： 10.1007/s10517-021-05152-0

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN： 0007-4888            Impact factor:   0.804


  8 in total

Review 1.  Trimetazidine in the Prevention of Tissue Ischemic Conditions.

Authors:  Manolis S Kallistratos; Leonidas E Poulimenos; Sofia Giannitsi; Pavlos Tsinivizov; Athanasios J Manolis
Journal:  Angiology       Date:  2018-06-10       Impact factor: 3.619

Review 2.  Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus.

Authors:  Brian W Gilbert; Max Sherard; Lindsey Little; Joshua Branstetter; Amber Meister; Joel Huffman
Journal:  Am J Cardiol       Date:  2017-11-28       Impact factor: 2.778

3.  Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.

Authors:  Caroline J Coats; Menelaos Pavlou; Oliver T Watkinson; Alexandros Protonotarios; Linda Moss; Rebecca Hyland; Khadija Rantell; Antonis A Pantazis; Maite Tome; William J McKenna; Michael P Frenneaux; Rumana Omar; Perry M Elliott
Journal:  JAMA Cardiol       Date:  2019-03-01       Impact factor: 14.676

Review 4.  Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure.

Authors:  Yuri M Lopatin; Giuseppe M C Rosano; Gabriele Fragasso; Gary D Lopaschuk; Petar M Seferovic; Luis Henrique W Gowdak; Dragos Vinereanu; Magdy Abdel Hamid; Patrick Jourdain; Piotr Ponikowski
Journal:  Int J Cardiol       Date:  2015-11-07       Impact factor: 4.164

5.  Anti-Ischemic Activity of Triamine ALM-802 under Conditions of Endothelial Dysfunction.

Authors:  V V Barchukov; I B Tsorin; A M Likhosherstov; M B Vititnova; G V Mokrov; T A Gudasheva; S A Kryzhanovskii
Journal:  Bull Exp Biol Med       Date:  2019-09-06       Impact factor: 0.804

6.  Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial.

Authors:  Tjark F Schwemer; Lukas Radziwolek; Navina Deutscher; Nadine Diermann; Susanne Sehner; Stefan Blankenberg; Felix W Friedrich
Journal:  J Cardiovasc Pharmacol Ther       Date:  2018-06-24       Impact factor: 2.457

7.  Ranolazine preserves and improves left ventricular ejection fraction and autonomic measures when added to guideline-driven therapy in chronic heart failure.

Authors:  Gary L Murray; Joseph Colombo
Journal:  Heart Int       Date:  2014-12-22

Review 8.  Ranolazine for Prevention of Atrial Fibrillation after Cardiac Surgery: A Systematic Review.

Authors:  Nirav Patel; Jeffery Kluger
Journal:  Cureus       Date:  2018-05-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.